Vistin Pharma ASA (VISTN.OL) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Norway · ISIN NO0010734122
Vistin Pharma ASA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 429.09 m NOK | 452.29 m NOK |
| Gross profit | 279.12 m NOK | 231.95 m NOK |
| Operating income | 85.30 m NOK | 92.35 m NOK |
| EBIT | 85.30 m NOK | 97.80 m NOK |
| Net income | 62.75 m NOK | 74.75 m NOK |
| Diluted EPS – continuing operations | 1.42 NOK | 1.69 NOK |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.
More stocks
- UNITRAD (0247.KL)
- Impact Develop (IMP.RO)
- TuHURA Biosciences, Inc./NV (HURA)
- United Recommend International Co Ltd (5321.TWO)
- LAKELAND INDUSTRIES INC (LAKE)
- IMMUCELL CORP /DE/ (ICCC)
- Lavras Gold Corp (LGC.V)
- Bailador Technology Investments Ltd (BTI.AX)
- Dellia Grp ASA (DELIA.OL)
- Major-Power Technology Co., Ltd. (6720.TWO)
- ATW Technology Inc (8097.TWO)
- Global AI, Inc. (GLAI)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.